Stem cell gene therapy: the risks of insertional mutagenesis and approaches to minimize genotoxicity.
about
The therapeutic potential of genome editing for β-thalassemiaThe effect of neonatal gene therapy on skeletal manifestations in mucopolysaccharidosis VII dogs after a decade.The various aspects of genetic and epigenetic toxicology: testing methods and clinical applicationsMolecular mechanisms of retroviral integration site selection.Modelling Fanconi anemia pathogenesis and therapeutics using integration-free patient-derived iPSCsQuantitative shearing linear amplification polymerase chain reaction: an improved method for quantifying lentiviral vector insertion sites in transplanted hematopoietic cell systemsDual-regulated lentiviral vector for gene therapy of X-linked chronic granulomatosis.Generation of integration-free induced hepatocyte-like cells from mouse fibroblastsAn assessment of the effects of ectopic gp91phox expression in XCGD iPSC-derived neutrophils.High efficiency restriction enzyme-free linear amplification-mediated polymerase chain reaction approach for tracking lentiviral integration sites does not abrogate retrieval bias.High expression of LMO2 predicts a favorable outcome in adult patients with BCR/ABL negative B-cell acute lymphoblastic leukemia.Assessing the risks of genotoxicity in the therapeutic development of induced pluripotent stem cellsEvaluating risks of insertional mutagenesis by DNA transposons in gene therapy.Long-term follow-up of foamy viral vector-mediated gene therapy for canine leukocyte adhesion deficiency.An ABCD1 Mutation (c.253dupC) Caused Diverse Phenotypes of Adrenoleukodystrophy in an Iranian Consanguineous Pedigree.Therapeutic potential of proteasome inhibitors in congenital erythropoietic porphyria.LIM domain only-2 (LMO2) induces T-cell leukemia by two distinct pathways.Bimodal high-affinity association of Brd4 with murine leukemia virus integrase and mononucleosomes.Prospects and challenges of reprogrammed cells in hematology and oncology.Development of gene therapy for thalassemia.Human artificial chromosome-based gene delivery vectors for biomedicine and biotechnology.CRISPR-Cas9 technology and its application in haematological disorders.Derivation and characterization of bovine induced pluripotent stem cells by transposon-mediated reprogramming.Bone regeneration in the stem cell era: safe play for the patient?Clinical potential of human-induced pluripotent stem cells : Perspectives of induced pluripotent stem cells.Engineering Natural Killer Cells for Cancer Immunotherapy.Application of Droplet Digital PCR for Estimating Vector Copy Number States in Stem Cell Gene TherapyDevelopment of safer gene delivery systems to minimize the risk of insertional mutagenesis-related malignancies: a critical issue for the field of gene therapy.A Universal Approach to Correct Various HBB Gene Mutations in Human Stem Cells for Gene Therapy of Beta-Thalassemia and Sickle Cell Disease.Clinical use of lentiviral vectors.Nonintegrating Direct Conversion Using mRNA into Hepatocyte-Like Cells
P2860
Q26766232-2150BABA-3B9F-4C5E-8F5A-D4EDE47DCAB2Q30540876-84C4C13D-E4CF-4C2F-8E30-8887AEE9FD53Q33716668-C1CB5A29-0198-4DFC-A58C-49A36FFA994DQ34249653-4EED921C-E2C1-44D7-AFE2-B1C717F681F2Q34918292-D87A7D44-4F38-4DAA-9561-1460E63DFD95Q35110771-E9CEFCB5-1719-4C3B-8622-436C3F07C090Q35618854-5921D22E-8F17-4610-BCF9-F46D1A2DFCC1Q36209829-06EE49FF-E65A-49E5-8D64-CFD6641EB300Q36358611-F6E3E65E-2F8B-4AC7-B455-43141B5BE92FQ36562607-7824DDEE-8591-4187-871B-69845DA401B4Q36640231-05D054A5-CDC6-4B65-9F10-B4CB0B39B70EQ36673714-198B49B4-F189-4908-9321-99055FD60D7EQ36698269-06FC2569-170E-4FFE-B530-EE4531930BBBQ36883869-7C8BC469-EC73-4F3D-A1A3-7E9CB55DBAEEQ37143422-41FA211E-4431-49F8-9E46-31B57F3DB744Q37318251-A21F9939-3B5D-40D0-9C2E-A9D1A3F0FBB5Q37499781-F1BE263C-132B-42B5-AC6F-C441578B7A6EQ37734367-15722D15-0ECC-4A7F-89BC-05A4745CAF44Q38031618-7AE984E5-BC45-4CD8-816C-7CEB3B46DB66Q38057725-721B6BFA-C0CB-4F3E-9FC2-632BECCB5013Q38183464-7601A89D-DFA5-4D70-8DBC-CBC105144069Q38822073-6EEEBB2F-F412-4BA7-901F-22B29A77217EQ38892567-8A6F2DE9-E487-4DA1-8BB5-42D944CB156CQ38941719-2A107CAA-28B1-4B3E-91CE-3881BFE5B2B5Q39024182-46CF6CF5-D5EC-4DDA-80D5-4D9318698541Q39408704-418661C7-7E48-4225-A905-5D203CB4D52AQ40414488-0CF4A9CB-2758-4FE4-8F58-34934699A18BQ41948139-F8F5735A-53EA-4909-835A-51DFF7E35247Q45874858-331E9ED7-66B5-442B-8137-1CD4967A69ACQ52589095-DAAE3A7F-ED9A-451E-9517-E473ACADC717Q57492704-8AAC468F-D7FF-42EC-84CA-F38C40929C01
P2860
Stem cell gene therapy: the risks of insertional mutagenesis and approaches to minimize genotoxicity.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Stem cell gene therapy: the ri ...... ches to minimize genotoxicity.
@ast
Stem cell gene therapy: the ri ...... ches to minimize genotoxicity.
@en
type
label
Stem cell gene therapy: the ri ...... ches to minimize genotoxicity.
@ast
Stem cell gene therapy: the ri ...... ches to minimize genotoxicity.
@en
prefLabel
Stem cell gene therapy: the ri ...... ches to minimize genotoxicity.
@ast
Stem cell gene therapy: the ri ...... ches to minimize genotoxicity.
@en
P2860
P1476
Stem cell gene therapy: the ri ...... ches to minimize genotoxicity.
@en
P2093
Chuanfeng Wu
Cynthia E Dunbar
P2860
P2888
P304
P356
10.1007/S11684-011-0159-1
P577
2011-12-27T00:00:00Z